Chugai Pharmaceutical : Roche Announces Global Phase III SUNMO Study Data for Relapsed/Refractory Diffuse Large B-Cell Lymphoma (Combination Therapy with Lunsumio and Polivy)
Roche Announces Global Phase III SUNMO Study Data for Relapsed/Refractory Diffuse Large B-Cell Lymphoma (Combination Therapy with Lunsumio and Polivy)
TOKYO, June 23, 2025 -- Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) announced that Roche issued a news release on June 20th regarding the data presentation of the Global Phase III SUNMO study for relapsed/refractory diffuse large B-cell lymphoma at the 18th International Conference on Malignant Lymphoma (ICML).
The study demonstrated a statistically significant and clinically meaningful improvement in its primary endpoints of progression-free survival (PFS) and objective response rate (ORR). The safety profile of the Lunsumio and Polivy combination was consistent with the known profiles of the individual study medicines.
Please refer to the link below for details of the news release:
Roche's Lunsumio and Polivy combination significantly prolongs remission for people with relapsed or refractory large B-cell lymphoma https://www.roche.com/media/releases/med-cor-2025-06-20
Trademarks used or mentioned in this release are protected by laws.
###
Attachments
Original document
Permalink
Disclaimer
Chugai Pharmaceutical Co. Ltd. published this content on June 23, 2025, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on June 23, 2025 at 02:36 UTC.
Chugai Pharmaceutical Co Ltd is a Japan-based company mainly engaged in the research, development, manufacture, sale, import and export of pharmaceutical products. The pharmaceutical products and medical devices for patients include ACTEMRA, Avastin, ALAGLIO, Aresensa, Kadosaira, Gazaiba, Seruseputo, Zeruborafu, Zeroda, Taruseba, Tecentoriku, Pajeta and other products. The products are mainly applied to the treatment of cancer, kidney diseases, kidney transplantation, bone and joint diseases such as rheumatoid arthritis, osteoporosis, knee osteoarthritis and locomotive syndrome, influenza, hemophilia and other diseases. The Company is also engaged in the provision of management services, transportation and storage services, as well as drug information literature research services. The Company operates within the domestic market and to overseas markets, including Switzerland, United Kingdom, Germany, France, China, Singapore, Korea and the United States.
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Chugai Pharmaceutical : Roche Announces Global Phase III SUNMO Study Data for Relapsed/Refractory Diffuse Large B-Cell Lymphoma (Combination Therapy with Lunsumio and Polivy)
